Niagen Bioscience posts investor presentation focused on NAD+ science and healthy-aging products - NAGE News | RalliesNiagen Bioscience posts investor presentation focused on NAD+ science and healthy-aging products
N
NAGE• Investor presentation outlines NAD+ strategy
- Niagen Bioscience outlined a strategy centered on NAD+ science, led by its patented nicotinamide riboside supplement franchise.
- Tru Niagen was positioned as the No. 1 NAD+ healthy-aging supplement in the U.S., supported by clinician sharing on FrontrowMD.
- Niagen Plus targeted a NAD+ IV and injections market estimated at about $500 million, citing improved administration time and fewer side effects.
- Niagen IV reported distribution in more than 1,700 clinics nationwide, including large wellness providers.
- The pipeline expanded beyond supplements into Nanocloud skincare and drug development for rare genetic diseases.
